Madkhali Ahmad A, Fadel Zahir T, Aljiffry Murad M, Hassanain Mazen M
Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia; Department of Oncology, McGill University, Montreal, Canada, .
Saudi J Gastroenterol. 2015 Jan-Feb;21(1):11-7. doi: 10.4103/1319-3767.151216.
Hepatocellular carcinoma (HCC) is an epithelial tumor derived from hepatocytes; it accounts for 80% of all primary liver cancers and ranks globally as the fourth leading cause of cancer-related deaths. HCC treatment is a multidisciplinary and a multimodal task, with surgery in the form of liver resection and liver transplantation (LT) representing the only potentially curative modality. However, there are variable opinions and discussions about applying these surgical options and using other supporting treatments. This article is a narrative review that includes articles published from 1984 to 2013 located by searching scientific databases such as PubMed, SCOPUS, and Elsevier, with the main keyword of hepatocellular carcinoma in addition to other keywords such as liver transplantation, liver resection, transarterial chemoembolization, portal vein embolization, bridging therapy, and downstaging. In this review, we focus mainly on the surgical treatment options offered for HCC, in order to illustrate the current relevant data available in the literature to help in applying these surgical options and to use other supporting treatment modalities when appropriate.
肝细胞癌(HCC)是一种起源于肝细胞的上皮性肿瘤;它占所有原发性肝癌的80%,在全球范围内是癌症相关死亡的第四大主要原因。HCC治疗是一项多学科、多模式的任务,肝切除和肝移植(LT)形式的手术是唯一具有潜在治愈可能的治疗方式。然而,对于应用这些手术选择以及使用其他支持性治疗存在不同观点和讨论。本文是一篇叙述性综述,纳入了通过检索科学数据库(如PubMed、SCOPUS和Elsevier)找到的1984年至2013年发表的文章,主要关键词为肝细胞癌,此外还有肝移植、肝切除、经动脉化疗栓塞、门静脉栓塞、桥接治疗和降期等其他关键词。在本综述中,我们主要关注为HCC提供的手术治疗选择,以阐明文献中现有的相关数据,帮助应用这些手术选择并在适当的时候使用其他支持性治疗方式。